Trial Profile
Randomized Study of the Efficacy and Safety of Transdermal Granisetron Compared With Intravenous and Oral Agent in the Control of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2017
Price :
$35
*
At a glance
- Drugs Granisetron (Primary) ; Granisetron; Granisetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Sponsors LG Life Sciences
- 17 Aug 2012 New trial record